FDA widens indication for Pradaxa

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

The FDA approved dabigatran for the treatment of deep vein thrombosis and pulmonary embolism in certain patients.

The anticoagulant dabigatran (Pradaxa, Boehringer Ingelheim) was approved in 2010 to reduce the risk of stroke in patients with nonvalvular atrial fibrillation. In August of 2013, the FDA agreed to review a supplemental New Drug Application for patients with deep vein thrombosis and pulmonary embolism.

The new indication includes patients who have been treated with a parenteral anticoagulant for five to 10 days, and in previously treated patients to reduce the risk of recurrent deep vein thrombosis and pulmonary embolism.

The approval was based on positive results from the RE-COVER and RE-COVER II trials, noninferiority trials that compared dabigatran with warfarin in patients with deep vein thrombosis and pulmonary embolism who were treated with parenteral anticoagulant therapy for five to 10 days. FDA reviewers also assessed results from RE-MEDY, a noninferiority trial that enrolled patients who had been previously treated for acute deep vein thrombosis and pulmonary embolism with anticoagulant therapy for three to 12 months; and RE-SONATE, a placebo-controlled trial with patients who had been previously treated for acute deep vein thrombosis and pulmonary embolism with an anticoagulant for six to 18 months.

The RE-COVER and RE-MEDY trials gave dabigatran the advantage for overall bleeding but found a higher rate of gastrointestinal bleeding with dabigatran. In RE-SONATE, dabigatran treatment substantially reduced the risk of recurrence compared with placebo but had higher rates of any bleeding, clinically relevant non-major bleeding and gastrointestinal bleeding.

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."